SHZ Healthcare Medical - Devices 300760.SZ

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

$ 140.01 -2.33 %

Operating on a global scale, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. specializes in providing a comprehensive range of medical devices and innovative healthcare solutions. Its extensive portfolio encompasses several key segments. Within patient monitoring and life support, the company manufactures crucial equipment such as patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, and endoscopes, along with associated accessories. This segment also delivers integrated solutions for emergency care, peri-operative management, critical care, and medical IT systems. For in-vitro diagnostics, Mindray offers sophisticated products including hematology and chemistry analyzers and their reagents, chemiluminescence immunoassay products, hemoglobin systems, flow cytometry instruments, and microplate readers and washers. These are further supported by solutions tailored for coagulation, urinalysis, and microbiology. The company additionally produces advanced medical imaging systems, covering both ultrasound and radiology products, and supplies a dedicated line of veterinary products. Founded in 1991, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. maintains its primary operational base in Shenzhen, People's Republic of China.

CEO: Hao Wu - https://www.mindray.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 259.20

Loading data...

300760.SZ vs S&P500

Loading data...

No data available.

Quick ratio

1.94

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

21.64

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

6.47

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

20.02 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

17.10 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.48

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.01

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

6.51

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

51.37 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
9.04 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.51 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.01 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.